Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1999 1
2000 1
2001 1
2002 1
2003 3
2004 2
2005 2
2006 4
2007 3
2008 5
2009 9
2010 7
2011 5
2012 7
2013 2
2014 5
2015 5
2016 7
2017 7
2018 4
2019 3
2020 4
2021 7
2022 4
2023 8
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
European Respiratory Society guidelines for the management of adult bronchiectasis.
Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. Polverino E, et al. Among authors: welte t. Eur Respir J. 2017 Sep 9;50(3):1700629. doi: 10.1183/13993003.00629-2017. Print 2017 Sep. Eur Respir J. 2017. PMID: 28889110 Free article.
The resulting guideline addresses the investigation of underlying causes of bronchiectasis, treatment of exacerbations, pathogen eradication, long term antibiotic treatment, anti-inflammatories, mucoactive drugs, bronchodilators, surgical treatment and respiratory physioth …
The resulting guideline addresses the investigation of underlying causes of bronchiectasis, treatment of exacerbations, pathogen eradication …
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.
Menzies-Gow A, Wechsler ME, Brightling CE, Korn S, Corren J, Israel E, Chupp G, Bednarczyk A, Ponnarambil S, Caveney S, Almqvist G, Gołąbek M, Simonsson L, Lawson K, Bowen K, Colice G; DESTINATION study investigators. Menzies-Gow A, et al. Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
This extension study recruited from NAVIGATOR and SOURCE and aimed to evaluate the long-term safety and efficacy of tezepelumab in individuals with severe, uncontrolled asthma. ...These findings are consistent with previous randomised, placebo-controlled studies and show t …
This extension study recruited from NAVIGATOR and SOURCE and aimed to evaluate the long-term safety and efficacy of tezepelumab in in …
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M; BORA study investigators. Busse WW, et al. Lancet Respir Med. 2019 Jan;7(1):46-59. doi: 10.1016/S2213-2600(18)30406-5. Epub 2018 Nov 8. Lancet Respir Med. 2019. PMID: 30416083 Clinical Trial.
BACKGROUND: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that has been shown to safely reduce exacerbations and improve lung function for patients with asthma. We assessed the long-term safety and efficacy of benralizumab for patie …
BACKGROUND: Benralizumab is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody that has been shown to safely reduce exac …
Chest Infections After Lung Transplantation.
Joean O, Welte T, Gottlieb J. Joean O, et al. Among authors: welte t. Chest. 2022 Apr;161(4):937-948. doi: 10.1016/j.chest.2021.10.014. Epub 2021 Oct 18. Chest. 2022. PMID: 34673023 Review.
Despite substantial progress in long-term follow-up strategies for lung transplant recipients, morbidity and mortality remain high, mostly because of the elevated infectious risk and the development of chronic lung allograft dysfunction. ...
Despite substantial progress in long-term follow-up strategies for lung transplant recipients, morbidity and mortality remain high, m …
Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial.
Köhnlein T, Windisch W, Köhler D, Drabik A, Geiseler J, Hartl S, Karg O, Laier-Groeneveld G, Nava S, Schönhofer B, Schucher B, Wegscheider K, Criée CP, Welte T. Köhnlein T, et al. Among authors: welte t. Lancet Respir Med. 2014 Sep;2(9):698-705. doi: 10.1016/S2213-2600(14)70153-5. Epub 2014 Jul 24. Lancet Respir Med. 2014. PMID: 25066329 Clinical Trial.
BACKGROUND: Evidence is weak for the ability of long-term non-invasive positive pressure ventilation (NPPV) to improve survival in patients with stable hypercapnic chronic obstructive pulmonary disease (COPD). ...No other intervention-related adverse events were reported. …
BACKGROUND: Evidence is weak for the ability of long-term non-invasive positive pressure ventilation (NPPV) to improve survival in pa …
HbA1c-dependent projection of long-term renal outcomes.
Arnold F, Kappes J, Rottmann FA, Westermann L, Welte T. Arnold F, et al. Among authors: welte t. J Intern Med. 2024 Feb;295(2):206-215. doi: 10.1111/joim.13736. Epub 2023 Nov 5. J Intern Med. 2024. PMID: 37925625
[Non-invasive ventilation].
Köhnlein T, Welte T. Köhnlein T, et al. Among authors: welte t. Internist (Berl). 2006 Sep;47(9):917-8, 920-2, 924 passim. doi: 10.1007/s00108-006-1684-x. Internist (Berl). 2006. PMID: 16912873 Review. German.
Pressure tight masks allow the ventilation of patients with severe respiratory or ventilatory insufficiency. Non-invasive ventilation may be used as short-term treatment for patients with acute ventilatory decompensation, as well as for long-term therapy at home for …
Pressure tight masks allow the ventilation of patients with severe respiratory or ventilatory insufficiency. Non-invasive ventilation may be …
The Differential Diagnosis of Dyspnea.
Berliner D, Schneider N, Welte T, Bauersachs J. Berliner D, et al. Among authors: welte t. Dtsch Arztebl Int. 2016 Dec 9;113(49):834-845. doi: 10.3238/arztebl.2016.0834. Dtsch Arztebl Int. 2016. PMID: 28098068 Free PMC article. Review.
METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed, and on pertinent guidelines. RESULTS: The term dyspnea refers to a wide variety of subjective perceptions, some of which can be influenced by the patient's emotional state. ...
METHODS: This review is based on pertinent articles retrieved by a selective search in PubMed, and on pertinent guidelines. RESULTS: The …
Bronchiectasis--diagnosis and treatment.
Rademacher J, Welte T. Rademacher J, et al. Among authors: welte t. Dtsch Arztebl Int. 2011 Dec;108(48):809-15. doi: 10.3238/arztebl.2011.0809. Epub 2011 Dec 2. Dtsch Arztebl Int. 2011. PMID: 22211147 Free PMC article. Review.
Macrolides seem to bring an additional benefit, though the studies that documented this involved only small numbers of patients. Long-term treatment with inhaled antibiotics and/or macrolides is indicated only if a benefit is seen within three months of the start of treatm …
Macrolides seem to bring an additional benefit, though the studies that documented this involved only small numbers of patients. Long-ter …
Biomarkers in community-acquired pneumonia.
Krüger S, Welte T. Krüger S, et al. Among authors: welte t. Expert Rev Respir Med. 2012 Apr;6(2):203-14. doi: 10.1586/ers.12.6. Expert Rev Respir Med. 2012. PMID: 22455492 Review.
However, for the evaluation of prognosis in community-acquired pneumonia, new cardiovascular biomarkers are superior compared with inflammatory markers, especially for the determination of long-term mortality. The combination of several biomarkers reflecting different path …
However, for the evaluation of prognosis in community-acquired pneumonia, new cardiovascular biomarkers are superior compared with inflammat …
103 results